Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
about
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug CombinationsTargeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Cytotoxic isoferulic acidamide from Myricaria germanica (Tamaricaceae).HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanatesPredictive biomarkers for cancer therapy with PARP inhibitors.Emerging signaling pathways in hepatocellular carcinoma.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
P2860
Q28552235-EEE07D9C-057B-42B6-B647-97E59A7A98AAQ34770525-C2F4B9FB-4042-4753-83EB-E57506548BC8Q35228413-FFB6F495-6C91-4404-85F3-7791BC7D049CQ35588352-D4DB7915-B922-44C5-8CAF-80FC1FAC7441Q37100231-762E659E-5879-4889-8507-9D94DBF413BDQ37378670-31BE9EF7-8952-4011-A750-77BE70A7DBB7Q38137764-B6B16D7F-7BCF-4587-A49F-2D9ED9020A65Q38155507-6399E396-F70D-4371-A842-91B2FFA33AD7Q38683171-0059E0B2-57C6-47D3-B818-24D7559381B9Q38907017-FE409DA4-A4BA-44A1-A41B-56F302B46277Q41872120-AFCDF075-EAED-4242-8338-A51D643E871BQ49275071-5F950560-2D98-4725-B4AC-60EF504825ED
P2860
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases.
@ast
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases.
@en
type
label
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases.
@ast
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases.
@en
prefLabel
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases.
@ast
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases.
@en
P2093
P2860
P356
P1433
P1476
Synergistic inhibition of hepa ...... poly (ADP-ribose) polymerases
@en
P2093
Aiwu Ruth He
Da-Qiang Li
Jeyanthy Eswaran
Jun-Xiang Zhang
Lopa Mishra
Mona Motwani
Rakesh Kumar
P2860
P304
P356
10.1002/HEP.25566
P407
P577
2012-06-01T00:00:00Z